While molecular subgrouping has revolutionized medulloblastoma classification, the extent
of heterogeneity within subgroups is unknown. Similarity network fusion (SNF) applied to …

Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated
with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive …

Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose
debilitating effects on the developing child, and highlight the need for molecularly targeted …

Purpose Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer
conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup …

Purpose: To retrospectively assess the apparent diffusion coefficient (ADC) for prediction of
malignancy and prognosis of malignant astrocytic tumors. Materials and Methods: The …

Purpose Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3,
and Group 4. Current medulloblastoma protocols stratify patients based on clinical features…

Background Patients with incomplete surgical resection of medulloblastoma are controversially
regarded as having a marker of high-risk disease, which leads to patients undergoing …

The development of targeted anti-cancer therapies through the study of cancer genomes is
intended to increase survival rates and decrease treatment-related toxicity. We treated a …

Medulloblastoma (MB) comprises a group of heterogeneous paediatric embryonal
neoplasms of the hindbrain with strong links to early development of the hindbrain 1, 2, 3, 4. …

BACKGROUND AND PURPOSE: The clinical relevance of proton MR spectroscopy needs
further clarification as to its usefulness and limitations. The purpose of this study was to …